PREVIOUS QUESTION:

 

NEXT QUESTION:

 

How is apremilast used to treat moderate or severe psoriasis?

ANSWER

Apremilast is an inhibitor of phosphodiesterase-4 (PDE-4), which controls inflammation within cells.

SOURCES:

American Academy of Dermatology. Bhosle, M. , June 2006. FDA. "FDA approves new psoriasis drug Taltz." “FDA approves Amjevita, a biosimilar to Humira. National Psoriasis Foundation.


Health and Quality of Life Outcomes

Reviewed by Stephanie S. Gardner on October 30, 2017

WAS THIS ANSWER HELPFUL

SOURCES:

American Academy of Dermatology. Bhosle, M. , June 2006. FDA. "FDA approves new psoriasis drug Taltz." “FDA approves Amjevita, a biosimilar to Humira. National Psoriasis Foundation.


Health and Quality of Life Outcomes

Reviewed by Stephanie S. Gardner on October 30, 2017

THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE. It is intended for general informational purposes only and does not address individual circumstances. It is not a substitute for professional medical advice, diagnosis or treatment and should not be relied on to make decisions about your health. Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. If you think you may have a medical emergency, immediately call your doctor or dial 911.

    This tool does not provide medical advice. See additional information.

    Other Answers On: